

ASX ANNOUNCEMENT

Brisbane, 1st May, 2017

ADMEDUS HSV-2 PHASE IIa RESULTS WEBINAR

- Admedus investor webinar Thursday, 4 May 2017
- 9am AEST Sydney/Melbourne/Brisbane time; 7am AWST Perth time

Admedus Limited (ASX:AHZ) today announced that it will hold an investor webinar on Thursday, 4 May 2017 to present the results of the HSV-2 Phase IIa program and provide a business overview on the rest of its immunotherapies programs including the HPV treatment program and its work in the area of RNA vaccines.

The webinar details

Date: 4 May, 2017

Time: 9am Australian Eastern Standard Time (AEST); 7am Australian Western Standard Time (AWST)

Please register to attend the webinar at:

<https://attendee.gotowebinar.com/register/2780413500734718467>

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

Website: www.admedus.com

For more information, please contact:

Dr Julian Chick
Chief Operating Officer | Admedus Limited
T: +61 (0)8 9266 0100
E: info@admedus.com

Media Europe
FTI Consulting
Simon Conway / Victoria Foster Mitchell
T: +44 (0) 20 3727 1000
E: admedus@fticonsulting.com

Signal Leadership Communication Inc.
Bob Pickard
T: +1 (647) 822 1000
E: bob.pickard@signaleadership.com

US Investor
Rx Communications Group, LLC
Melody A. Carey
T: +1 917 322 2571
E: mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com.